

# Contents

---

List of Contributors xv

Preface xxv

## I

### SETTING THE SCENE, BOTANICAL, GENERAL AND INTERNATIONAL ASPECTS

1. The *Cannabis* Plant: Botanical Aspects 3  
S. FARAG, O. KAYSER
2. The Biosynthesis of Cannabinoids 13  
F. DEGENHARDT, F. STEHLE, O. KAYSER
3. Increasing Plant Concentrations of THC and  
Implications on Health Related Disorders 24  
V. VINDENES, J. MØRLAND
4. Age as a Predictor of Cannabis Use 33  
D. BERGEN-CICO, R.D. CICO
5. Lifetime Cannabis Use and Cognition  
in Psychosis Spectrum Disorders 44  
M.J. CUESTA, A.M. SÁNCHEZ-TORRES, R. LORENTE-OMEÑACA,  
L. MORENO-IZCO
6. A Profile of Synthetic Cannabinoid Users 53  
A.N. SANDERS, J.M. STOGNER
7. Dual Disorders in Cannabis Misuse 61  
F. ARIAS-HORCAJADAS, N. SZERMAN, P. VEGA,  
I. BASURTE, B. MESÍAS
8. Cannabis Use and Cognitive Function 70  
C. EVREN
9. Cannabis, Migration, and Psychosis Onset 79  
A. KOKONA, I. TARRICONE, M. DI FORTI, E. CARRA
10. The Global Epidemiology and Disease  
Burden of Cannabis Use and Dependence 89  
L. DEGENHARDT, A.J. FERRARI, W.D. HALL
11. International Aspects of Cannabis Use  
and Misuse: the Australian Perspective 101  
D.J. ALLSOP, W.D. HALL
12. International Aspects of Cannabis Use  
and Misuse: Egypt 110  
O.M.E. ABDEL-SALAM, A.F. GALAL, S.A. ELSHEBINEY,  
A.E.D.M. GAAFAR
13. Cannabis Body Packing: A Caribbean  
Perspective 122  
S.O. CAWICH, D. DAN, V. NARAYNSINGH

## II

### PERSONAL, SOCIAL AND COMMUNITY ASPECTS OF CANNABIS USE

14. Gender Differences in Cannabis  
Use Disorders 131  
R. SECADES-VILLA, S. FERNÁNDEZ-ARTAMENDI
15. The Role of Age in the Onset and Further  
Development of Cannabis Use Disorders 138  
S. BEHRENDT
16. Effects of Cannabis Use on Neurocognition  
in Adolescents and Emerging Adults 151  
N.E. WRIGHT, K.E. MAPLE, K.M. LISDAHL



17. Correlates and Consequences of Prenatal Cannabis Exposure (PCE): Identifying and Characterizing Vulnerable Maternal Populations and Determining Outcomes for Exposed Offspring 160  
L.K. BRENTS
18. Cannabis and Clubbing: Relevance of Cannabis and Polydrug Use in the Clubbing Culture Today 171  
D.A. HERZIG, S. BACHMANN
19. Cannabis and Sexual Behavior 180  
G. SCIMECA, C. CHISARI, M.R.A. MUSCATELLO, C. CEDRO, G. PANDOLFO, R. ZOCCALI, A. BRUNO
20. Friendships and Cannabis Use 188  
J.H. BOMAN IV, C. HECK
21. Students' Knowledge of Cannabis 198  
M. DROZD, J. SOBCZYŃSKI
22. Childhood Trauma and Cannabis: Risk Factors in Severe Mental Disorders? 208  
M. AAS, I. MELLE
23. Parent's Influence on Children's Cannabis Use 215  
S. MILLER, J.T. SIEGEL, W.D. CRANO
24. Cannabis Users and Premorbid Intellectual Quotient 223  
L. FERRARO, L. SIDELI, D. LA BARBERA
25. Cannabis and Traffic Accidents 234  
R.B. DE BONI, R.P. LIMBERGER, T.R.V. SOUSA
26. Drug-Related Pictures, Attentional Bias, and Cannabis Use 247  
D. ASMARO
27. Cannabis Use and First-Episode Psychosis Patients (FEP) 257  
I. GONZÁLEZ-ORTEGA, M. MARTÍNEZ-CENGOTITABENGOA, A. GONZÁLEZ-PINTO
28. Cannabis, Associative Memory, fMRI, and the Implicit Association Test 267  
S.L. AMES, A.W. STACY
29. Stress Response in Cannabis Users and Psychosis 278  
M. BIOQUE, H.-H. TSENG, R. MIZRAHI
30. Motivation in Chronic Cannabis Use 288  
R. HIRST, L. SODOS, S. GADE, L. RATHKE
31. Cannabis Use and Its Association to Mental Illness: A Focus on Mood and Anxiety Disorders 298  
S. LEV-RAN, D. FEINGOLD
32. Cannabis Use and Well-Being 308  
J. ALLEN, M.D. HOLDER, Z. WALSH
33. Craving and Cannabis: A Potential Paradox 317  
M.J. LOFLIN, M. EARLEYWINE
34. Delta-9-Tetrahydrocannabinol and Catalepsy-Like Immobilization 326  
N. EGASHIRA
35. The Interactive Nature of Cannabis and Schizophrenia Risk Genes 335  
T. KARL, J.C. ARNOLD
36. Neuroimaging Findings in Adolescent Cannabis Use and Early Phase Psychosis 345  
C.E. CROCKER, J. COOKEY, P.G. TIBBO
37. Cannabis Smoking in Adult Schizophrenia: A Cognitive and Functional Magnetic Resonance Imaging Perspective 357  
K. PAQUIN, T. LECOMTE, S. POTVIN
38. The Long-Lasting Effects of Cannabis Use on Movement and Brain Regions that Control Movement 372  
G. TODD, J.M. WHITE

### III

## CANNABIS, BEHAVIOR, PSYCHOPATHOLOGY AND NEUROPATHOLOGY



39. Assessment of Cannabis Acute Effects on Driving Skills: Laboratory, Simulator, and On-Road Studies 379  
P. BONDALLAZ, H. CHTIOUI, B. FAVRAT, E. FORNARI, C. GIROUD, P. MAEDER
40. Chronic Cannabis Use and Axonal Fiber Connectivity 391  
N. SOLOWIJ, A. ZALESKY, V. LORENZETTI, M. YÜCEL
41. Microglial Activation and Cannabis Exposure 401  
L. CUTANDO, R. MALDONADO, A. OZAITA
42. Cannabis and Psychosis: Correlation, Causality, and Consequences 413  
D. BASU, P. PARAKH
43. Cannabis Use in Bipolar Disorder 422  
T.V. LAGERBERG
44. Cannabis Use in Epilepsy—Risks and Benefits 431  
M. HOLTkamp, M. HAMERLE
45. Cannabis, Cannabinoids, and Visceral Pain 439  
R. ABALO, M. ISABEL MARTÍN-FONTELLES
46. Cannabis and Postoperative Analgesia 450  
S.O. CAWICH, U. DEONARINE, H.E. HARDING, D. DAN, V. NARAYNSINGH
50. Cardiovascular Effects of Cannabis Usage 481  
S. MENAHEM
51. Cannabis and Stroke 486  
P.A. BARBER
52. Cannabis Smoking and the Lung 494  
D.P. TASHKIN
53. Cannabis and Hepatic Injury 505  
S.A. NADA, O.M.E. ABDEL-SALAM, A.A. SLEEM
54. Cannabis Allergy: More Than a Bad Trip 517  
A.L. VAN GASSE, V. SABATO, M.M. FABER, C.H. BRIDTS, D.G. EBO
55. Marijuana and Breastfeeding 527  
M.G. HILL, K.L. REED
56. Hypocretins/Orexins and Addiction: Role in Cannabis Dependence 533  
Á. FLORES, R. MALDONADO, F. BERRENDERO
57. Regulatory Role of Cannabinoids for Skin Barrier Functions and Cutaneous Inflammation 543  
T. TÜTING, E. GAFFAL

## IV

### CANNABIS, ORGANS, TISSUES AND NON-CNS ASPECTS

47. Chronic Cannabis Abuse and Thyroid Function 461  
U. BONNET
48. Cannabis Hyperemesis Syndrome 466  
U. BONNET
49. Cannabis and Cannabinoids and the Effects on Gastrointestinal Function: An Overview 471  
M. SALAGA, R. ABALO, J. FICHNA

## V

### PHARMACOLOGY AND CELLULAR ACTIVITIES OF CANNABINOID AND ENDOCANNABINOID

58. Cannabinoids and the Cannabinoid Receptors: An Overview 553  
D. LU, D.E. POTTER
59. Signaling and Regulation of the Cannabinoid CB<sub>1</sub> Receptor 564  
M.R. HUNTER, D.B. FINLAY, M. GLASS
60. Allosteric Modulation of the Cannabinoid CB<sub>1</sub> Receptor 573  
E.E. CAWSTON, M.R. HUNTER, M. GLASS



61. Polymorphisms of the CB2 Cannabinoid Receptor 584  
P. KUMAR, Z.-H. SONG
62. Chemistry of Cannabinoid Receptor Agonists 592  
M. AGHAZADEH TABRIZI, P.G. BARALDI
63. The Endocannabinoid System as a Target for New Antiseizure Drugs 606  
L.R. VILELA, A.C.P. DE OLIVEIRA, M.F. MORAES, F.A. MOREIRA, R.N. TAKAHASHI
64. Pharmacological Aspects of Anandamide and 2-Arachidonoylglycerol as Bioactive Lipids 616  
M. ALHOUAYEK, G.G. MUCCIOLI
65. Pharmacological Aspects of NMDA Receptors, mGluR5, and Endocannabinoids 630  
Y. IZUMI, C.F. ZORUMSKI
66. Peripheral CB1 Receptors and Ghrelin in Feeding Regulation: Pharmacological Implications 639  
L. ORIO, R. GÓMEZ DE HERAS, F. RODRÍGUEZ DE FONSECA
67. Pharmacological Aspects of Novel Antiobesity Agents Related to Cannabinoids 649  
L. HERNANDEZ-FOLGADO
68. Cannabinoid Reward and Dependence: Focus on the Main Psychoactive Ingredients of Marijuana in Preclinical Studies 659  
G. PANAGIS
69. Peroxisome Proliferator Activated Receptors and Cannabinoids 671  
E. MUÑOZ, F. POLLASTRO, O. TAGLIALATELA-SCAFATI, G. APPENDINO
70. The Protein-Protein Interactions of Cannabinoid Receptor Interacting Protein 1a (CRIP1a) and Cannabinoid 1 Receptor: The Molecular Mechanism Study Through an Integrated Molecular Modeling Approach 680  
M.H. AHMED, Y. ZHANG
71. Synthetic Cannabinoids: a Summary of Selected Phenomena with Respect to Behavioral Pharmacology and Abuse Liability 691  
B.T. BURROWS, L.R. WATTERSON, J. EGNATIOS, M.F. OLIVE

## VI

## EFFECTS OF SPECIFIC NATURAL AND SYNTHETIC CANNABINOIDS

72. The Role of 5-HT<sub>1A</sub> Receptor, and Nausea and Vomiting Relief by Cannabidiol (CBD), Cannabidiolic Acid (CBDA), and Cannabigerol (CBG) 703  
E.M. ROCK, L.A. PARKER
73. Genetic and Molecular Aspects of Addiction with Tetrahydrocannabinol 713  
T. JANUS, A. MACHOY-MOKRZYŃSKA, K. BOROWIAK
74. Effects of  $\Delta^9$ -Tetrahydrocannabinol in Human Breast Cancer 722  
S. TAKEDA, E. IKEDA, H. OKAZAKI, K. WATANABE, H. ARAMAKI
75.  $\Delta^9$ -THC and COX-2 Signaling 729  
J. ZHANG, C. CHEN
76. Cannabinoids and the Addictive Effects of Nicotine 739  
L.V. PANLILIO, S.R. GOLDBERG
77. Cannabinoid Regulation of Intraocular Pressure: Human and Animal Studies, Cellular and Molecular Targets 748  
A. ALOWAY, A. KUMAR, A.S. LAUN, Z.H. SONG
78. Ocular Delivery of Tetrahydrocannabinol 760  
G.R. ADELLI, P. BHAGAV, M.A. REPKA, W. GUL, M.A. ELISOHLI, S. MAJUMDAR
79. The Role of  $\gamma$ -Aminobutyric Acid in the Interoceptive Effects of Oral  $\Delta^9$ -Tetrahydrocannabinol in Humans 770  
J.A. LILE, J.S. FOGEL, T.H. KELLY
80. The Role of  $\Delta^9$ -Tetrahydrocannabinol in Diabetes Mellitus 779  
Z.M. COSKUN, S. BOLKENT
81. Cannabidiol: An Overview of its Antipsychotic Properties 787  
R.F. PERES, V. ALMEIDA, V.C. ABILIO



82. Cannabidiol for the Treatment of Epilepsy: An Overview of Possible Mechanisms of Action and Preclinical and Human Studies 795  
R. GUIMARÃES DOS SANTOS, J.E.C. HALLAK, A.W. ZUARDI, A.C. DE SOUZA CRIPPA, J.A. DE SOUZA CRIPPA
83. Cannabidiol and Neuroprotection: Evidence from Preclinical Studies 802  
N. SCHRÖDER, V.K. DA SILVA, J.E.C. HALLAK, A.W. ZUARDI, J.A. DE SOUZA CRIPPA
84. Cannabinoids as Potent Inhibitors of Human CYP1 Enzymes 813  
K. WATANABE, S. YAMAORI, K. MASUDA, T. KATSU, S. NARIMATSU, I. YAMAMOTO
85. The Synthetic Analog of  $\Delta^9$ -Tetrahydrocannabinol (THC): Nabilone. Pharmacology and Clinical Application 821  
R.E. BALTER, M. HANEY
86. Synthetic Cannabinoids in Dementia 828  
S. AMANULLAH, K. SHIVAKUMAR, S. HASSAN, A. CANFIELD, J. COLE
87. Synthetic Cannabinoid Receptor Agonists (Spice) as New Recreational Psychoactive Substances 839  
A. HELANDER
88. Accidents and Synthetic Cannabinoids in Blood of Drivers 848  
S.S. TUV, V. AUWÄRTER, V. VINDENES
91. Beneficial Effects of Cannabis and Related Compounds on Sleep 877  
I.M.P. LINARES, J.A.S. CRIPPA, M.H.N. CHAGAS
92. Cannabinoid-Based Medicines for the Treatment of Gilles de la Tourette Syndrome 883  
A.S. KANAAN, K.R. MÜLLER-VAHL
93. Cannabidiol and Multiple Sclerosis 893  
M. MECHA, A. FELIÚ, F.-J. CARRILLO-SALINAS, C. GUAZA
94. Cannabinoids and Their Effects on Painful Neuropathy 905  
D. SELVARAJAH, R. GANDHI, S. TESFAYE
95. Cannabis for Basal Ganglia Disorders (Parkinson Disease and Huntington Disease) 917  
O.M.E. ABDEL-SALAM
96. Medical Cannabis for the Treatment of Inflammatory Bowel Disease 931  
A. LAHAT
97. Cannabidiol for the Treatment of Drug Use Disorders 939  
R.G. DOS SANTOS, J.E.C. HALLAK, A.W. ZUARDI, J.A. DE SOUZA CRIPPA
98. Cannabinoids and Effects on the Gastrointestinal Tract: A Focus on Motility 947  
G. VERA, J. FICHNA, R. ABALO
99. Potential Medical Uses of Cannabigerol: A Brief Overview 958  
S. DEIANA

---

## VII

### MEDICINAL CANNABIS USE

89. Cannabis and Synthetic Cannabinoids for Cancer Patients: Multiple Palliative Indications Together With Promising Laboratory Antineoplastic Effects 859  
D. ZALMAN, G. BAR-SELA
90. The Use of Medical Marijuana in the Treatment of Psychiatric Disorders 869  
T. TELLIOĞLU, Z. TELLIOĞLU

---

## VIII

### SCREENING, DIAGNOSIS, AND TREATMENT

100. The Cannabis Abuse Screening Test (CAST) and Its Applications 971  
L. BASTIANI, R. POTENTE, M. SCALESE, V. SICILIANO, L. FORTUNATO, S. MOLINARO



|  |      |   |             |
|--|------|---|-------------|
| 101. Screening of Synthetic Cannabinoids<br>E.L. ØIESTAD, R. KARINEN, K. HAUGLAND, Å.M.L. ØIESTAD                          | 981  | 109. Cognitive Behavioral Therapy in Cannabis Use Disorder<br>E.M. GUVEN, U.M. CAMSARI, O. SENORMANCI, G. OGUZ                      | 1056        |
| 102. On-Site Drug Testing for Cannabis<br>A.A. FERNÁNDEZ   | 998  | 110. The Cannabis Withdrawal Syndrome—Symptoms and Time Course<br>M. HESSE, B. THYLSTRUP  | 1066        |
| 103. Cannabinoids in Oral Fluid: Identification and Interpretation of Analytical Results<br>C. MOORE                       | 1007 | 111. School-Based Cannabis Prevention Programs<br>C. ARIZA, F. SÁNCHEZ-MARTÍNEZ, A. PÉREZ   | 1074        |
| 104. Cannabinoids in Exhaled Breath<br>O. BECK   | 1018 | 112. The CapOpus Trial for Cannabis Use Disorders<br>C.R. HJORTHØJ, M. NORDENTOFT   | 1086        |
| 105. Barriers to Treatment Seeking for Cannabis Dependence<br>P. GATES, J. COPELAND  | 1025 | 113. Treating Cannabis Use Disorders Through Technology-Assisted Interventions: The Telephone and Internet<br>P. GATES, J. COPELAND | 1093        |
| 106. Pharmacotherapies for Cannabis Use Disorders<br>A.L. McRAE-CLARK  | 1030 | 114. Reducing Cannabis Use With a Real-Time Intervention Using Mobile Technology<br>M. KELLS, L.A. SHRIER                           | 1101        |
| 107. Self-Initiated Cannabis Use Cessation in Adolescents and Emerging Adults<br>J. TSAI, M. LITTLE, S. SUSSMAN            | 1036 | Cannabis Neuropathology Resources and Recommended Reading<br>R. RAJENDRAM, V.B. PATEL, V.R. PREEDY                                  | 1111        |
| 108. Treating Cannabis-Dependent Adolescents with Family Therapy: The Case of Multidimensional Family Therapy<br>H. RIGTER | 1047 | <b>Index</b>  | <b>1115</b> |

## Online Contents

### I

#### SETTING THE SCENE, BOTANICAL, GENERAL AND INTERNATIONAL ASPECTS

|  |    |
|--|----|
| e1. Tetrahydrocannabinol Concentration and Genetic Characterization of Cannabis<br>F. CASCINI, I. BOSCHI | e1 |
|--|----|

### II

#### PERSONAL, SOCIAL AND COMMUNITY ASPECTS OF CANNABIS USE

|  |     |
|--|-----|
| e2. Cannabis Use in Youth Subcultures<br>M. PAWSON, B.C. KELLY | e11 |
|--|-----|



### III

#### CANNABIS, BEHAVIOR, PSYCHOPATHOLOGY AND NEUROPATHOLOGY

- e3. Aggressive Behavior and Cannabis Use e19  
W. LIU, H. PETRAS

- e4. COMT Genotypes, Cannabis Use, and  
Psychosis: Gene-Environment Interaction  
Evidence from Human Populations, and Its  
Methodological Concerns e29  
M. FATJÓ-VILAS, C. PRATS, L. FAÑANÁS

- e5. Neuroimaging and Genetics of the Acute  
and Chronic Effects of Cannabis e42  
R. MARTÍN-SANTOS, J.A. DE SOUZA CRIPPA, S. BHATTACHARYYA

- e6. Gray Matter, Lateral Ventricle Volumes,  
and Executive Functioning in Cannabis Users  
with First-Episode Psychosis e53  
P.J. CUNHA, P.G.P. ROSA, F.L.S. DURAN, L.C. SANTOS,  
J.A.S. CRIPPA, G.F. BUSATTO, M.S. SCHAUFELBERGER

- e7. Cannabis Use and Attention-Deficit/  
Hyperactivity Disorder: Potential Moderators e64  
K.E. MAPLE, N.E. WRIGHT, K.M. LISDAHL

### IV

#### CANNABIS, ORGANS, TISSUES AND NON-CNS ASPECTS

- e8. Cannabis and Oral Health: Deleterious  
Effects on Periodontitis and Dental Implants e72  
G. NOGUEIRA-FILHO

- e9. Does Cannabis Use Increase the Risk  
of Developing Cancer in Humans? e80  
R.C. CALLAGHAN, M. VERDICHEVSKI, T.M. FYFE, J.M. GATLEY

- e10. Cannabis and the Use of Amphetamine-Like  
Substances e101  
A. PORCU, M.P. CASTELLI

### V

#### PHARMACOLOGY AND CELLULAR ACTIVITIES OF CANNABINOIDS AND ENDOCANNABINOIDS

- e11. Cannabinoid Signaling in Glioma Cells  
and Therapeutic implications e111  
A. ELLERT-MIKLASZEWSKA, I. A. CIECHOMSKA, B. KAMINSKA

### VI

#### EFFECTS OF SPECIFIC NATURAL AND SYNTHETIC CANNABINOIDS

- e12. Cannabidiol as an Antioxidant e122  
R.S. BORGES, A.B.F. DA SILVA

- e13. The Anxiolytic Effects of Cannabidiol  
(CBD) e131  
A.W. ZUARDI, J.A. DE SOUZA CRIPPA, J.E.C. HALLAK,  
A.C. CAMPOS, ES. GUIMARÃES

- e14. New Ethological and Morphological  
Perspectives for the Investigation of  
Panicolytic-Like Effects of Cannabidiol e140  
N.C. COIMBRA, J. MENDES-GOMES, J.A. DA SILVA,  
T. DOS ANJOS-GARCIA, F. ULLAH, R.C. ALMADA

- e15. Spice Use Among United States  
Military Personnel e150  
H.A. MORRIS, J.M. STOGNER

### VII

#### MEDICINAL CANNABIS USE

- e16. Cannabis Use in Fibromyalgia e158  
M. FARRÉ, A. FARRÉ, J. FIZ, M. TORRENS



VIII

SCREENING, DIAGNOSIS, AND TREATMENT

e17. Short Instruments to Screen for "Problematic" Cannabis Use in General Population Surveys e168 B. ANNAHEIM, S. LEGLEYE

e18. Self-report of Cannabis Use e185 T. VAN DER LINDEN

e19. CANDIS Program: Modular Treatment of Cannabis Use Disorders e193 E. HOCH, H. ROHRBACHER

e20. Engaging Cannabis Users in Treatment e202 F KAY-LAMBKIN, A. HEALEY, A. BAKER, W. SWIFT, L. THORNTON, A. TURNER